Altogether, these results suggest that hotspot POLE‐mutated tumors in CRC have molecular characteristics, such as MMR‐P status and noncodon 12 mutations of KRAS/NRAS and noncodon 600 BRAF mutation (P = 0.02). This evidence concerns the gene KRAS and colorectal carcinoma.